ABSTRACT Symptoms of congestive heart failure frequently reflect abnormalities in both systolic and diastolic performance. While much work has been reported regarding the mechanisms by which positive inotropic and vasodilator therapy affect systolic performance, little is known about their effect on diastolic function. In 12 patients with diffuse congestive cardiomyopathy micromanometer left ventricular and aortic pressure measurements were recorded simultaneously with two-dimensionally targeted M mode echocardiograms and thermodilution-determined cardiac output. Each patient received dopamine (2, 4, and 6 gg/kg/min), and dobutamine (2, 6, and 10 ,ug/kg/min), and 10 received nitroprusside (0.125 to 2.0 gg/kg/min). Baseline hemodynamics were characterized by low cardiac index (2.1 ± 0.7 liter/min/m2, mean ± SD), high left ventricular end-diastolic pressure (24 ± 10 mm Hg), and increased end-diastolic (6.8 + 1.0 cm) and end-systolic dimensions (6.0 1.0 cm). All patients had abnormal left ventricular pressure decay with a prolonged time constant (67 ± 20 msec) and reduced peak diastolic lengthening rates. Dopamine and dobutamine decreased the time constant of relaxation and increased the peak lengthening rate. Dobutamine also reduced the minimum diastolic pressure from 14 ± 7 to 10 + 9 mm Hg (p < .01); neither drug reduced end-diastolic pressure. In fact, dopamine elevated end-diastolic pressures in seven patients, despite more rapid pressure decay. Diastolic pressure-dimension relations after dopamine and dobutamine showed a leftward shift with a reduced end-systolic chamber size, but no significant changes in passive chamber stiffness. Nitroprusside decreased left ventricular minimum diastolic pressure by 4 ± 2 mm Hg and end-diastolic pressure by 7 ± 4 mm Hg (p < .0 1). It did not consistently accelerate left ventricular pressure decay at the doses tested. The decreased end-diastolic pressure with nitroprusside was due to a reduced end-diastolic dimension in five patients. In the other patients, all of whom had elevated right atrial pressures, diastolic pressure-dimension relations showed a parallel downward shift after nitroprusside. Thus, positive inotropic therapy with /31-adrenoceptor agonists enhances early diastolic distensibility by accelerating relaxation, augmenting filling, and reducing end-systolic chamber size. Vasodilator therapy is much more effective in lowering diastolic pressures. In some patients this is due to a reduction in extrinsic restraint of the pericardium and/or right ventricular interaction, while in others it simply reflects a decrease in chamber size without alterations in ventricular passive chamber properties. Circulation 74, No. 4, 815-825, 1986. AS OUR UNDERSTANDING of the pathophysiology of the heart failure syndrome has improved, certain classes of drugs have assumed prominent roles in its treatment. 
a logical result of the discovery of abnormal peripheral vascular loading conditions, which elevate resistance to ventricular ejection and produce high filling pressures. 1 Positive inotropic therapy remains a reasonable approach since a reduction in the contractile state of the myocardium appears central to the disease process. 2 Little attention has been focused on striking diastolic abnormalities found in the failing heart. In this study we used isovolumetric pressure decay, left ventricular lengthening rates, diastolic pressure-chamber size relations, and pressure measurements throughout diastole to characterize the diastolic properties found in diffusely dilated, cardiomyopathic ventricles.
We hypothesized that positive inotropic therapy should be accompanied by an acceleration in isovolumetric pressure decay and enhancement of early diastolic distensibility. To study this issue, the myocardial 13-adrenoceptor agonists dobutamine and dopamine were used.3 4 Although both of these drugs affect systemic vascular tone, only dopamine is capable of modulating vascular tone through peripheral dopaminergic receptors. 4 In addition, a-receptor activation may further modify dopamine's actions. 5 We further hypothesized that vasodilating agents may decrease diastolic pressures by several mechanisms. Diastolic pressures should decrease to a greater degree than chamber size if ventricular interaction and/ or pericardial restraint are present. We chose to study the well-known agent nitroprusside, a drug with nonspecific venous and arterial vasodilator actions.
By studying all three agents in each patient, we hoped to gain a more complete understanding of the differential effects of positive inotropic and vasodilator therapy on diastolic function in patients with congestive cardiomyopathy. In so doing, additional insights into the pathophysiology and treatment of congestive heart failure could be revealed.
Methods
Patient population. Twelve patients with congestive cardiomyopathy were studied. There were eight men and four women who ranged in age from 26 to 62 years (mean = 48). The cause of the cardiomyopathy was idiopathic in eight patients and probably due to systemic hypertension in four patients. Although mild-to-moderate coronary artery disease (one to two vessels with at least 50% diameter narrowing) was present in five patients, no patient had a history of clinical infarction. Patients were included in the study only if their echocardiograms were of high quality and showed a diffusely hypocontractile, dilated left ventricle. Patients with significant regional wall motion abnormalities were excluded from the study. By Doppler examination seven had no significant mitral regurgitation and five had moderate regurgitation without intrinsic mitral valve abnormalities. The QRS complex was prolonged to 110 msec or greater on the resting electrocardiogram of four patients. All patients had symptomatic heart failure despite therapy with digoxin and diuretics; New York Heart Association functional class ranged from 2 to 4 (mean = 3.4) while on therapy. All patients gave written informed consent to a protocol approved by the Human Investigation Commitee of the University of Chicago.
Cardiac catheterization. Patients were studied while in the fasting state and after premedication with diazepam (5 mg orally) and atropine (0.5 mg subcutaneously). Vasodilators were withheld for 48 hr in the two patients taking them.
Right and left heart catheterizations were performed from the femoral artery and vein in all patients. A Millar catheter with a high-fidelity pressure transducer at the distal end (Model SPC-484A) was used in two patients and a catheter with an additional pressure transducer 5 cm proximal to the end (Model SVPC-684D) was used in the remaining patients. The catheter tip was soaked in warm saline for 45 to 60 min before calibration and subsequent insertion. The side port of the arterial sheath was used for pressure reference relative to micromanometer pres- 
Results
In tables 1, 2, and 3 standard hemodynamic and echocardiographic data obtained during control periods, after each dose of dopamine and dobutamine, and at the highest dose of nitroprusside are presented. Baseline left ventricular function. All patients had significant cardiac dysfunction. Cardiac index (2.1 ± 0.7 liters/min/m2), left ventricular shortening fraction (1 1 ± 4%), and maximum + dP/dt (855 ± 247 mm Hg/sec) were reduced, while left ventricular end-diastolic pressure was elevated (24 + 10 mm Hg). Minimum left ventricular diastolic pressure was 14 ± 8 mm Hg. Left ventricular chamber size was increased in all patients, with an average end-diastolic dimension of 6.8 + 1.0 cm and an average end-systolic dimension of 6.0 +-1.0 cm. figure 2 . This accelerated pressure decay lowered diastolic pressures; minimum left ventricular pressure decreased from 14 ± 8 to 11 + 9 mm Hg (p < .05) at the maximum dose (figure 3), but there was no significant (p < .08) reduction in end-diastolic pressure (figure 4). In figure 5 the left ventricular dia-THERAPY AND PREVENTION-CARDIOMYoPATHY stolic pressure-dimension data are shown for the control period and the period after dobutamine at its maximum dose. In early diastole dobutamine caused a leftward shift due to the reduced end-systolic chamber size and reduced pressures relative to chamber diameter. After the diastolic pressure nadir the diastolic pressure-dimension relation for dobutamine was superimposable on the control state relation. The passive chamber stiffness constant, a, was not significantly altered (12.0 + 9.4 vs 18.0 + 25.6). Dobutamine also increased peak lengthening rate, as shown in figure 6 for normalized lengthening rates. Dopamine. The 6 gg/kg/min infusion of dopamine was not given to two patients due to an excessive rise in left ventricular diastolic pressure and right atrial mean pressure. Dopamine augmented systolic performance to a degree comparable to that seen with dobutamine.
Dopamine accelerated pressure decay and increased peak lengthening rates ( figure 6 ). There was a reduction in end-systolic dimension from 6.1 ± 1.1 to 5.9 ± 1.1 cm (p < .05) and in end-diastolic dimension from 6.9 ± 1.0 to 6.7 ± 1.1 cm (p < .05).
In figure 7 diastolic pressure-dimension relations are shown for the patients after separation into two groups according to right atrial pressures. Those 
end-diastolic pressure simply due to a decrease in end-diastolic dimension. In contrast those patients with elevated right atrial pressures (n = 5) showed a parallel downward shift due to a decreased end-diastolic pressure without a significant change in dimension. These patients also had more dilated left ventricles.
Discussion
This study demonstrates that isovolumetric pressure decay is very slow, lengthening rates are reduced, and the diastolic pressure-dimension relation is altered in patients with congestive cardiomyopathy. Resultant diastolic pressures are grossly elevated. These striking abnormalities in diastolic function and their modification by positive inotropic and vasodilator agents link the known pharmacologic actions of dopamine, dobutamine, and nitroprusside to distinctive hemodynamic effects that improve left ventricular diastolic performance.
The elevation of filling pressures in patients with congestive cardiomyopathy has been attributed predominantly to two causes. First is chamber dilation due to the disease process itself. This is further exacerbated by renal retention of sodium and water; chamber dilation causes a rightward shift in the diastolic pressurevolume relation in the ventricle. This normally produces higher end-diastolic pressures, but in those with longstanding congestive cardiomyopathy a new pressure-volume relation is achieved that blunts the rise in diastolic pressures. 24 - FIGURE 7. The average diastolic pressure-dimension relations are shown before and after nitroprusside for two groups of patients grouped according to right atrial pressure values. Those whose data appear on the left had normal right atrial pressure (n = 5) and responded to nitroprusside with a reduction in pressure and chamber size. Those whose data appear on the right had elevated right atrial pressure (n = 5) and responded to nitroprusside with a reduction in intracavitary pressure out of proportion to any change in chamber size, suggesting that pericardial restraint and/or ventricular interaction was operative.
sensitive not only to the myocardial deactivation process but also to the prevailing loading conditions.'8 A reduction in end-systolic chamber size and/or wall stress will accelerate pressure decay. A reduction in end-systolic load may be produced by agents with positive inotropic, vasodilator, or combined activity. A reduction in end-systolic size occurred in our patients in response to nitroprusside, but no consistent effect on pressure decay was seen. It thus appears that the ,B,-adrenoceptor agonists we have studied have a more profound effect on ventricular pressure decay than does nitroprusside, at least in the doses of nitroprusside administered. Reduced end-systolic diameter and accelerated pressure decay after dobutamine and dopamine account for the leftward shift in the diastolic pressure-diameter relation and slight downward shift in early diastole. The early diastolic pressure-diameter coordinates obtained during dopamine and dobutamine infusion show that for a given chamber dimension, pressure is less ( figure 7 ). This presumably reflects more rapid and more complete decay from the preceding systole. Figure 8 shows four possible mechanisms for alteration of the diastolic pressure-volume relation in patients with congestive cardiomyopathy. Many or all of these factors may be present and influence the response to therapy. In addition, viscous factors may further modify diastolic function. 19 33 Even changes in filling pressure in the same patient may not represent a parallel change in preload. The response to nitroprusside in patients with elevated right atrial pressures shows that end-diastolic pressure may decrease significantly with no or minimal change in left ventricular chamber size. Most pharmacologic studies have used filling pressures (e.g., pulmonary capillary wedge or left ventricular end-diastolic) as indexes of chamber preload. These are typically plotted against a measurement of systolic performance, such as stroke volume or stroke work. The resultant curves represent the net interaction of numerous variables, making the interpretation of changes in curve position or individual data points difficult. In addition, in the calculation of constants of chamber stiffness or myocardial stiffness it is assumed that intracavitary pressures are true distending pressures. In the interpretation of drug action the potential influence of many factors needs to be considered, including varying pericardial pressure and ventricular interaction.
In the five patients in our study with grossly elevated right atrial pressures there was a parallel downward shift in the diastolic pressure-dimension relation after nitroprusside, with a reduction in diastolic pressure The possibility that dopamine increased the degree of pericardial restraint and/or ventricular interaction is suggested by a tendency toward increased end-diastolic pressure without an increase in chamber size ( figure  5 ). Indeed, dopamine increased right atrial pressure in seven of the 12 patients. In the venous system there are no dopamine, receptors but there are a-adrenoceptors that are activated by dopamine. 37 Our results are quite consistent with dopamine causing venoconstriction and increasing central blood volume.
In the normal heart dopamine and dobutamine accelerate pressure decay, increase peak lengthening rates, and leave the passive diastolic pressure-dimension relation unaltered.7' 23 Nitroprusside has been previously shown to accelerate pressure decay in normal animals. 18 In our patients with severe cardiomyopathy this finding was not consistently demonstrated. The presence of low systolic pressures limited the dose of nitroprusside in several patients and may have contributed to the lack of acceleration in pressure decay. Yet even at these doses, shifts in the diastolic pressure-diameter relation were demonstrated. In the normal heart a parallel downward shift with nitroprusside is not expected, since baseline right atrial pressures would be normal. Thus, certain abnormalities in patients with congestive cardiomyopathy can modify the effects of medications compared with the response in those with a normal circulation.
Finally, several patients had mitral regurgitation of a moderate degree without mitral leaflet abnormalities.
THERAPY AND PREVENTION-CARDIOMYOPATHY
Variation in the degree of mitral regurgitation during the administration of all three drugs could have altered diastolic pressures and lengthening rates. However, we did not observe any clear differences in the response to the three medications in those with and those without regurgitation. Further studies with a larger number of patients with significant regurgitation are needed to specifically address this question.
We conclude that positive inotropic therapy and vasodilator therapy produce significant but distinctively different effects on diastolic function in patients with congestive cardiomyopathy. The pharmacologic actions of each agent produce hemodynamic effects that are also dependent on the specific pathophysiologic abnormalities present in the individual patient.
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